❤️ Cold Email Automation
🤖 AI for Cold Outreach
🔥 Advanced Email Warm-up
🕵️ Mass Email Personalization
❤️ Free Tools
Pricing
Blog
Alzheon, Inc. develops innovative medicines for neurodegenerative disorders, with a focus on their lead Alzheimer’s candidate, ALZ-801. This oral tablet blocks neurotoxic amyloid oligomers and builds on the safety and efficacy of tramiprosate.